Success Metrics

Clinical Success Rate
71.4%

Based on 15 completed trials

Completion Rate
71%(15/21)
Active Trials
1(4%)
Results Posted
93%(14 trials)
Terminated
6(22%)

Phase Distribution

Ph phase_1
4
15%
Ph phase_2
4
15%
Ph phase_3
3
11%
Ph phase_4
10
37%
Ph not_applicable
4
15%

Phase Distribution

4

Early Stage

4

Mid Stage

13

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
4(16.0%)
Phase 2Efficacy & side effects
4(16.0%)
Phase 3Large-scale testing
3(12.0%)
Phase 4Post-market surveillance
10(40.0%)
N/ANon-phased studies
4(16.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

65.2%

15 of 23 finished

Non-Completion Rate

34.8%

8 ended early

Currently Active

1

trials recruiting

Total Trials

27

all time

Status Distribution
Active(1)
Completed(15)
Terminated(8)
Other(3)

Detailed Status

Completed15
Terminated6
unknown3
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
1
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (16.0%)
Phase 24 (16.0%)
Phase 33 (12.0%)
Phase 410 (40.0%)
N/A4 (16.0%)

Trials by Status

withdrawn27%
completed1556%
recruiting14%
unknown311%
terminated622%

Recent Activity

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT07314333Phase 1

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

Completed
NCT04132557

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Completed
NCT05957055Phase 2

Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes

Recruiting
NCT03187353Phase 4

IMProving Executive Function Study

Completed
NCT02259517Not Applicable

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

Terminated
NCT01415440Not Applicable

Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD

Completed
NCT02635035Phase 2

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

Completed
NCT04727476

The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders

Unknown
NCT02712996Phase 4

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children

Completed
NCT02170298Phase 4

Lisdexamfetamine's Effect In ADHD in the Brain and Cognition

Terminated
NCT01490216Phase 1

Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence

Terminated
NCT01486810Phase 1

Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence

Completed
NCT03070509Phase 4

Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients

Unknown
NCT01977625Phase 4

LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women

Completed
NCT01924429Phase 4

Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation

Completed
NCT01714310Phase 2

Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation

Completed
NCT01986777Not Applicable

LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy

Withdrawn
NCT02034201Phase 1

Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence

Completed
NCT01324024Phase 4

Attention & Memory Impairments in Menopausal Women

Completed
NCT01986764Not Applicable

E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
27